History of organ transplantation via the two-way paradigm by Starzl, TE et al.
---
Anesthesia 
and Transplantation 
Edited by 
Michael D. Sharpe, M.D., F.R.C.P.C. 
Associate Professor. Department of Anaesthesia, 
University of Western Ontario Faculty of Medicine, and 
Director. W. E. Spoerel Intensive Care Unit, 
London Health Sciences Centre, London, Ontario 
and 
Adrian W. Gelb, M.B., Ch.B., F.R.C.P.C. 
Professor and Chairman, Department of Anaesthesia, 
University of Western Ontario Faculty of Medicine, 
London Health Sciences Centre, London, Ontario 
With 63 Contributing Authors 
UTTERWORTH 
EINEMANN 
Boston Oxford Auckland Johannesburg Melbourne New Delhi 
Chapter 1 
History of Organ Transplantation 
via the Two-Way Paradigm* 
Thomas E. Starzl, Noriko Murase, and Anthony J. Demetris 
Chapter Plan 
The Immunologic Barrier 
The One-Way Paradigm 
Rejection 
Tolerance 
Graft -versus-Host Disease 
Clinical Bone Marrow Transplantation 
Clinical Organ Transplantation 
The Two-Way Paradigm 
Whole-Organ Transplantation 
Whole-Organ Transplantation versus Bone 
Marrow Transplantation 
Importance of History 
The story of how whole-organ transplantation came 
to be a clinical discipline has been told elsewhere 
by many of those who were directly involved. I The 
kidney dominated events through 1959,2 but in the 
late 1950s, canine transplant models were devel-
oped to study intra-abdominal and thoracic organs. 
Pig and rodent models came later. 
·Portions of this chapter were previously published in The 
Lancet (TE Starzl, AJ Demetris. N Murase, et at. Cell migra-
tion. chimerism, and graft acceptance. Lancet 1992;339: 
1579-1582) and the Journal of the American Medical Asso-
cilll;on (TE Stant. AJ Demetris. Transplantation milestones: 
viewed with one-and two-way paradigms of tolerance. 
JAM A 1995;273:876-879). 
Each organ-defined specialty has had its histo-
rians, but they have been preoccupied with a suc-
cession of events rather than with the poorly 
understood biological principles by which all 
organs can escape rejection. This conventional 
approach is characterized by noting the first suc-
cessful allotransplantation of the kidney,3 liver,4 
heart,S lung,6 pancreas,7 intestine.s multiple abdom-
inal viscera,9 and bone marrowKfl-f~ Such mile-
stones are important, but the concern here is the 
steps by which organ transplantation was devel-
oped empirically and the understanding of what 
had been accomplished that came only later. Such 
generic information may be of use to anesthesi-
ologists who care for various organ transplant 
recipients. 
The Immunologic Barrier 
In December 1954, Joseph E. Murray unequivo-
cally demonstrated the potential benefit of human 
whole-organ replacement with an identical twin 
kidney donor. His achievement was symbolic 
only, showing with an identical twin organ what 
was already known to be possible with skin 
grafts. Seven years later, the father of modern 
immunology, Macfarland Burnet, wrote in the 
New EngLand Journal of Medicine, "much thought 
has been given to ways by which tissues or 
organs not genetically and antigenetically identi-
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Figure 1-1. The one-way paradigm: Transplantation is conceived as involving a unidirectional immune reaction: host-versus-
graft (HVG) reaction with whole organs (A) and graft-versus-host (GVH) reaction with bone marrow or other lymphopoietic 
transplants (B). 
cal with the patient might be made to survive and 
function in the alien environment. On the whole, 
the present outlook is highly unfavorable to suc-
cess." 1,\ 
The One-Way Paradigm 
Rejection 
What was the genetically determined barrier? 
Although details are obscure, there was little mys-
tery after 1944 about the general meaning of trans-
plant rejection, after its elucidation by Peter 
Medawar as an immunologic evenl. I4 Medawar's 
contribution created the image of a tissue (or 
organ) allograft as an island in a hostile recipient 
sea (Figure l-IA). 
Tolerance 
In contrast, how allografts or xenografts can escape 
rejection with or without the aid of immunosuppres-
sion has been one of the most arcane subjects in 
biology since Billingham. Brent, and Medawar 
described acquired tolerance in 1953. 15. 16 A simple 
explanation for the tolerance in their special model 
was at first beguiling. Immunocompetent adult 
spleen cells were injected in utero or perinatally into 
mice that had not yet evolved the immunologic 
equipment to reject them. The engrafted cells flour-
ished. perpetuated themselves. and. in effect, 
endowed the recipient with the donor immune sys-
tem. Thereafter. the chimeric mice failed to recog-
nize donor-strain skin or other donor tissues as alien. 
In this second landmark contribution from 
Medawar's laboratory. tolerance was explained as a 
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switch in immunologic apparatus, It was consistent 
with the definition of transplantation immunology 
as a unidirectional immune reaction (the "one-way 
paradigm"). Main and Prehn \7 strengthened this 
view by demonstrating the same tolerance outcome 
as that of Billingham. Brent. and Medawar in irra-
diated adult mice. Main and Prehn reconstituted the 
hematolymphopoietic cells of their cytoablated 
mice with bone marrow, Hundreds of subsequent 
tolerance-induction experiments in animals. and 
eventually clinical bone marrow transplantation. 
seemed to depend on a similar natural. or iatro-
genically imposed. defenseless recipient state (Fig-
ure I-IB). 
Graft-versus-Host Disease 
The anticipated clinical application of this kind of 
tolerance induction was temporarily derailed in 
1957. when it was realized that an immunologically 
Defenseless recipient 
Biliingham-Brent·Medawar 
Cytoablation (x-ray, drugs) 
Parent -) offspring F1 hybrid 
active graft could tum the tables and reject the recip-
ient (graft-versus-host disease [GVHDj), Billingham 
and Brent showed in their mouse model!H and 
Simonsen in chickens!9 that this risk (also called 
runt disease) was roughly proportional to the extent 
of the major histocompatibility complex (MHC) bar-
rier. Such disparities became measurable in humans 
after identi fication of the HLA by Dausset. 20 
Terasaki. and others.2! For many years. the compli-
cation of GVHD in rodent22 and large animal irradi-
ation chimera models23- 26 forestalled the clinical use 
of HLA-mismatched bone marrow cells or other 
mature immunocytes. either for immunologic recon-
stitution for purely hematologic purposes or as a 
means of facilitating whole-organ graft acceptance, 
Clinical Bone Marrow Transplantation 
Nevertheless. a strategy for clinical bone marrow 
transplantation eventually was assembled directly 
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Figure 1-1. CUlllllllled. The two-way paradigm: Transplantation is seen as a hidlrectlLlnal and mutually canceling immune 
reaction that is predominantly HVG with whole-organ grafts (C) and predominantly GVH with bone marrow grafts (D). 
from the rodent experi ments, but with similar 
histocompatibility-imposed restrictions. 23 After 
recipient cytoablation with total body irradiation 
(TBI) or cytotoxic drugs. stable chimerism could 
be induced in humans by the infusion of donor 
bone marrow if there was a good HLA match. 
Otherwise. the incidence of GVHD was intolera-
ble. After successful engraftment. maintenance 
immunosuppression frequently was not needed. 
mimicking the kind of acquired immunologic tol-
erance originally described by Billingham. Brent, 
and Medawar l5 . III and then by Main and Prehn. I? 
The eventual success of clinical bone marrow 
transplantation 10-12 was a straight-line extension 
from these rodent models. as Donnel Thomas 
( (990) has observed. 23 
Clinical Organ Transplantation 
Total Bod\' Irradiation 
The achievement of clinical bone marrow trans-
plantation effectively detached the surgeons from 
a scientific base because there was no explanation 
for successful engraftment. Nevertheless, by the 
time of the first successful bone marrow transplan-
tation. surgeons had already recorded many suc-
cessful human whole-organ transplantations 
(mostly kidneys) under continuous immunosup-
pression. without dependence on HLA matching or 
the complication of GVHD. and as it turned out. 
without host preconditioning. In fact. precondi-
tioning with sublethal TBI was used in the first 
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successful renal allotransplantation. described by 
Merrill et al. in 1960.1 The kidney recipient, how-
ever, whose donor was his fraternal (dizygotic) 
twin brother, was not given bone marrow, which 
was a significant departure from the Billingham-
Brent-Medawar framework. The recipient's own 
bone marrow recovered. and the transplanted kid-
ney and patient survived for 20 years. Six addi-
tional examples of protracted kidney graft survival 
(longer than I year) after recipient irradiation with-
out marrow were recorded in Paris over the next 36 
months. 27. 28 Five of the six donors were more dis-
tant relations than a fraternal twin. and two were 
genetically unrelated. 28 However. these were iso-
lated successes in a sea of failures. 
Chemical Immunosuppression 
The frustration continued after Murray et aL 29 
introduced 6-mercaptopurine and its analogue. aza-
Cytoablation (x-rays, drugs) 
I 
thioprine, for human renal transplantation. This fol-
lowed extensive experimental studies. first with 
rodent skin transplantation)!) .11 and then with canine 
kidney transplant models. ~9K )2-14 The drugs were 
originally developed as antileukemic agents by 
Elion et al. 35 and were first demonstrated to be 
immunosuppressive by Schwartz and Dameshek. 36 
Although the sixth patient treated by Murray with 
one or the other of these myelotoxic drugs had 
function of a nonrelated renal allograft for 17 
months. the clinical results were poor at first. c9. 37 
similar to those with TBl. 
The Double-Drug Breakthrough 
The tidal wave of whole-organ transplant cases 
began in 1962, when azathioprine was combined 
with prednisone to reverse rejection.)8 More impor-
tant. the subsequent need for maintenance immuno-
suppression frequently declined, and in occasional 
"""-~--"-"----------------------------
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cases, treatment could be stopped. The same 
sequence has been shown with all other organs 
transplanted and with all the immunosuppressive 
regimens (Figure 1-2). Agents introduced later 
were more potent and reliable in chaperoning the 
desired chain of events: antilymphocyte globulin,39 
cyclosporineI~o and tacrolimus EchpMSFK~1 Despite 
their diversity, all these drugs seemed, in a funda-
mentally similar way, to have allowed something to 
change in the host. the graft, or both. But what was 
that something'? 
The one-way paradigm of transplantation 
immunology that had gained ascendency nearly a 
half-century before did not provide answers to that 
question. The false conception of a unidirectional 
reaction was never seriously challenged after it was 
seemingly supported by studies with the one-way 
mixed lymphocyte reaction introduced in 1963 by 
Bach and eirschhorn-l~ and Bain et alY These in 
vitro techniques (so-called minitransplant models) 
generated thousands of increasingly sophisticated 
cellular and ultimately molecular studies of unidi-
rectional immunologic reactions. Ironically, the 
resulting plethora of new information sometimes 
resembled an exponentially expanding phone book 
filled with wrong numbers. Most seriously, the 
tlawed context I ured successive generations of 
investigators into the trap of believing that tolerance 
induction for whole-organ recipients (the "holy 
grail") lay in variations on the HLA-limiting strat-
egy Llsed for bone marrow transplantation. which 
included host preconditioning in preparation for a 
variety of donor leukocyte preparations. 
4lJ 
Figure 1-2. Pattern of postopera-
tive events with whole-organ allo-
graft acceptance in the framework 
of the one-way paradigm. (HVG = 
host-versus-graft [reaction1.) 
The Two-Way Paradigm 
Whole-Organ Transplantation 
A plausible explanation for the success of the empir-
ically developed whole-organ transplantation proce-
dures did not emerge until 1992. Then, a study of the 
surviving pioneer kidney and liver recipients from 
the earliest clinical trials revealed that donor leuko-
cytes of bone marrow origin. which are part of the 
structure of all complex grafts (passenger leuko-
cytes+1. -l5). had migrated from the organs to ubiqui-
tous sites in the recipient and survived for up to 30 
years. ~hK ~T Thus, organ allograft acceptance was 
associated with the cryptic survival of a small frag-
ment of extramedullary donor marrow, including 
stem cells (depicted as a bone silhouette encased by 
the kidney in Figure I-I C), which was disseminated 
throughout the recipient after the transplantation and 
assimilated into the much larger immunologic net-
work of the host. In the meantime, the cells that left 
the graft were replaced by recipient immune cells 
moving in the opposite direction. The end result was 
a small number of residual donor leukocytes 
(microchimerism) in both graft and host. 
From this information. a revision of transplanta-
tion immunology was possible. In the new view. the 
immunologic confrontation after whole-organ trans-
plantation could be seen as bidirectional (GVH as 
well as HVG) and mutually I:anceling (Figure 1-3), 
provided that the participants in the David-and-
Goliath mismatch could survive the initial 
onslaught. In a clinical context. but not in several 
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donor-specitic and recipient-specitic nonreactivity 
evolves accounts for blindfolding of the npected 
HLA effect. In addition to cxplaining why the HLA 
matching effect is blindfolded, this bidirectional 
canceling effect of the two cell populations explains 
why GVHD does not develop after li\er. intestinal. 
1l1ultivisceral. and heart-lung transplantation, 
despite the heavy lymphoid content of those organs. 
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I illn after \\ hille-organ transplant;ltI()n yya~ undcrstood 
()I' at least susceptible to expenl11ental inquiryK-l"l~ It 
was clcar why organ grafts arc Inherently tolero-
gelllC. why HL-\ matching IS S(l p()orl\' predicti\'c 
I" outu)me, and why CiVHD LlllL" Ilot de\el'lp after 
rhe Il'ansplantation lIt 1I11111ulllliogicaily adlYe 
Dr~lthK such as thc li\er and Ilttestlne, 
\\ith the I\\o-\\ay 11lu[U;iI c'dnLellation impliLlt 
;11 litis L'(lncept. the Ill" llr blunting ul :In HL.\ 
11l~ltdlln~ elfect IS easy to understand, \\'ith cal'll 
lurther k\d of hlstllincomp~t1lbt1ffyDK the reCiprocal 
d'kct i, pustulated tll escalate h()th \\a\ s. pro\lding 
rhe proce" Is iDh~lperoned \\ Ith ,In eltcL"lI\e 
II11I11UIHlsllppreS'\\L' lIl11brelf,1 I Figure 1--+1. The 
,-unseqlient dWIndling l1l Ihe malL'hing effect 'I' 
Historic efforts to give extra donor antigen in the 
form of bone marrow"'; llr donor blood trans 1'11-
IiEFnsR~-DED were hampered in design or execution by 
the assumption that the infused cell., \\ould be 
destroyed without rccipieltl preconditioning, by the 
fustifiable anxiety about CVHD if the host was 
preconditioned, and by a lacl- of information about 
the appropriate timing of thc infusions, The new 
information Ihat Lhimcrisl11 i ... a naturally ol:curring 
ewnt after whole-organ transplantation,l>.17 exposed 
a pcrioperatlw window 01 opportunity. In this win-
dow. unaltered IlL,\-inull11palibk bonL' l11arrmv or 
donor-specilic hl()od tran~lusion wa~ predicted to 
he sate \\ i1hout rl'ClpIL'1lI preparatlllll (II' ;Inv de\'ia-
Illlil Irol11 the !:!l'lIenl' pr;lctii"e~ 01 il11l11l1llll~rppres­
'Illn for 1\IHl!c-llrgan tr;lI1splantatioll. 1\ hldl had 
e\(ll\'ed Irom the 'lnglllal ;I/,alitlopnne-preLinisonc 
1(lrmula, '\ 
rhe \ alidlt) (II this ,Irategy 1\ as \cl'ilied in 
Ilnprcl'onLillioned I'l'ClplenlS III cada\clx l-idneys, 
fi\ers, hearts. and lUll!!" \\hll \\l'rC gl\CIl Ii~ x lOS 
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donor bone marrow cells per kg recipient body 
weight at the same time as organ transplantation 
under standard FK506-prednisone treatment (Fig-
ure 1_5).57 Chimerism estimated at more than 1.000 
times that occurring in conventional whole-organ 
recipients was reliably and safely produced and sus-
tained. Persistent blood chimerism (usually greater 
than 17c). a trend toward donor-speci fic nonreactiv-
ity. and a high rate of patient and graft survival has 
marked these bone marrow-augmented recipients 
as an advantaged cohort. They are the tirst patients 
to undergo HLA-mismatched cadaveric organ trans-
plantation with the reasonable prospect of eventu-
ally being drug free. The process of tolerance 
induction and drug weaning is expected to take 
5-10 years In most patients who are given mis-
matched organs. [n ~ome patients. the drug-free 
state may never be attained. 
Mutual 
Natural 
Immunosuppression 
Figure 1-4. Explanation for the 
loss of an HLA-matching effect 
with whole-organ transplantation. 
(Rx = immunosuppression.) 
Whole-Organ Transplantation versus Bone 
Marrow Transplantation 
With the discovery that whole-organ transplantation 
caused spontaneous chimerism. it was realized that 
the apparently vast gap between the bone marrow 
and whole-organ transplantation fields merely 
ret1ected entrenched ditferences of treatment strat-
egy (Figure 1-6). The mutually censoring immuno-
logic limbs were being left intact with organ 
transplantation. whereas the recipient limb was 
deliberately removed (cytoablation) in preparation 
for bone marrow grafting procedures. It is doubtful 
that it is ever possible (much less desirable) to com-
pletely eliminate the entire recipient immune system 
with the cytoablation techniques of bone marrow 
transplantation. Although this was long assumed to 
have occurred in successful cases (see Figure I-I B). 
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Figure 1·6. The growth of separate disciplines of bone marrow and whole-organ transplantation from the seed planted by 
Peter Medawar dunng World War II. It was recognized in 1992 that these seemingly disparate disciplines were mirror images 
caused by different treatment strategies. (GYHD = graft-versus-host disease.) 
publicationsi. complete with waste."63 In Cohn's 
opinion. the reason for the slow conceptual 
advancement in this branch of science has been the 
immunologists' preference for small theories that 
explain one or only a few facts (articulated by 
MitchisonM ) over the development of generalized 
principles that explain all facts (coherence of con-
text). It would be hard to tind a better way to illus-
trate the consequences of a small theory than those 
derived from the durable one-way paradigm. which 
was blindly accepted despite its failure to explain 
what was seen daily in every transplantation clinic 
and laboratory. Virtually no hint of the two-way 
paradigm can be found in the literature before the 
description in June 1992 of microchimerism in 
organ recipients. If the spontaneous development 
of chimerISm after organ transplantation had been 
recognized 30 years ago. it would have been possi-
ble to correctly interpret observations in splenocyte 
and bone marrow transplant experiments reported 
in 1960-ILJ62 hy Simonsen(»)' no and Michie. 
Woodruff. and Zeiss."7 The hypothesis of these ear-
lier workers-that acquired tolerance must result 
from a two-way (donor-recipient) immune reac-
tion-resembled the hypothesis that was later used 
to explain organ graft acceptance. Their great idea 
was abandoned because it could not be proved. 
thereby delaying a true understanding of transplan-
tation immunology for a third of a century. 
Beacons of understanding shine forward as well 
as backward. Understanding the history of transplan-
tation in terms of the two-way paradigm provides the 
intellectual means to devise better treatment strate-
gies. including the achievement of drug-free toler-
ance and. ultimately. xenotransplantation. 
References 
I. Tcrasaki PI (.:d). History of Transplantation: Thirty· 
Five Recollections. Los Angeles: UCLA Tissue Typing 
Laboratory. 1<)<) 1 . 
, Woodruff WMA (cd). The Transplantation of Tissues 
and Organs. Spnngtield. IL: Thomas. 1960. 
J. Memll JP. \\urray JE. Harrison JH. et al. Successful 
homotransplantation ()f the ~fdney between non-identi-
cal twms. N Engl J \led 1960:262:1251-1260. 
al 
lee 
n 
~E ~-
~d by 
lla~es 
r<.:al-
lIsed 
I Idea 
.,ved. 
.plan-
, well 
,plan-
<.:sthc 
,Irate-
toler-
~fll rt \-
l'vping 
. ~"ful 
"knll-
History of Organ Transplantation via the Two-Way Paradigm 11 
-\ 
). 
fJ. 
7. 
8. 
'). 
III 
II. 
Starzl TE. Groth CG. Brettschneider L. et al. Ortho-
topic homotransplantatiOn uf the hUlllan liver. Ann Surg 
I96S: 168:392-.415. 
Barnard C:'oJ. What we have learned about heart trans-
plants. J Thorae CanlIl1va,,: Surg i'lfJX.56A57-.468. 
Derom F. Barbier F. Ringolr S. ct al. Ten-month sur-
vival after lung homotransplantation in man. J Thorae 
Cardiovasc Surg 1971 :61 : h~R~p"S 
Kelly WD. Lillehei RC. \1erkel FK. et al. Allotransplan-
tation of the pancreas and duodenum along with the kid-
ney in diabetic nephropathy Surgery IlJ6 7:61 :pOT~UPTK 
Goulet O. Revillon Y. Brousse :sJ. d al. Successful small 
howel transplantation In an Intant TransplantatIOn 
IlJl)2:53Y .. O-9 .. 3 
St::U-ll TE. Rowe M. Tmjo S. et al Transplantation of mul-
Ilpk abdominal v"cera. JA\IA I YXlJ:2h I: 1 .... 9-1 .. 57. 
Bach FH. Bone-marrow transplantalion in a pallem wnh 
the \Viskott-Aldrich syndrome. Lan,,:t 1968:2: 1364--1 ~SSK 
\Iathe G. Amiel JL. Schwaflt:nherg l.. et al. Haemato-
poietic chimera In man after allogenIC I homologous) 
hone marrow transplantation. B \11 1%3:( Dec. 28): 
1SPP~1S"DRK 
12. Gatti RA. Meuwissen HJ. Allen HD. et al. Immunolog-
ical reconstilUlIon of se.x-Imkt'd Ivmphopenic immuno-
logical deticiency L.ancet I 'lhS:2. 1K1Sfg~f"DS9K 
13. Burnet FM. The new approach ll' IInmunology. :sJ Engl 
J \Ied 1961:26 .. : O-y~q 
14. i\kdawar PB. Tht: behav ",r JIld t"te 01 skin aUlOgratts 
and skin homografts in rahh!!>. J .·\nat 1') .... :78: 176-199. 
15. Billingham RE. Brent L. \kdawar PH. ",.\ctively acquired 
tolerance" of foreign cells. :\ature IlJ:i3: 172:603-606. 
16. Billingham R. Brent L. \kdawar P Quantitative studies 
,'n tissue transpiantallon Immunltv. III. .. \ctivelv 
acquired tolerance. Philos Trans R Soc Lond I Bioi) 
1956:239:357-.412. 
17. \Iain 1\1. Prehn RT Succc,,(ul ,kill homt1grafts atter 
the administration 01 high dllIa~t: X radiation and 
homologous hone marrow. J '1atl Cancer Inst 
1955: I 5: 1MOP~ 1029 
18. Billingham R. Brent L. .\ simple method for inducing 
tolerance of skin IHlIlhlgralts in mice. Transplant Bull 
1957:467-71. 
19. Simonsen M. The impact on the developing embryo 
and new horn animal of adult homologous cells. Acta 
Pathol MicroblOl Scand 1lF~T:-yEF:"ul 
20. Daussct J. The H!...\ Adventure. In PI Terasaki [t:dl. 
History of HL\: Ten KecolkclIons. Los Angeil:s: 
I 'CLA Ti"ue Typl ng Laboratory. 1l)l)O: I ~OEFK 
~ 1 rcf:Jsakl PI (cLil. ei~tl1ry ul HL.\. Tl!o oelKK:ollelDtinn~K 
Llls Angeles: l·CL.\ TI"ue 1\ ping Laboratorv. I 'NO. 
Trenlin JJ Induced t"lerance and "homologllus d,,-
ease" ill X-trradlated mi,'e prntecled wtth hOllHllogous 
hone marrow Pnll' c,(lC Exp 13iol \kd 1')'i7:96: 
1Ky9~f"" 
2.\' Thomas ED. Allo~enelc \larn'" t irafting-A Story ot 
\fan ~fnd Dug. In PI Terasakt ledl. Historv "I Trans-
plantation: Thirty-Five Recollections. Los Angeles: 
L'CLA Press. 1991:379-394. 
2 ... \lannick lA. Lochte HL. Ashley CA. et al. A function-
ing kidney homotransplant in the dog. Surgery 1959;46: 
821-828. 
25. Hume DM. Jackson BT. Zukoski CF. et al. The homo-
transplantation of kidneys and of fetal liver and spleen 
after wtal hody Irradiation. Ann Surg 1960: 152: 
354-373. 
26. Rapaport FT. Bachvarotf RJ. Mollen N. et al. Induction 
of unresponsiveness to major transplantable organs in 
adult mammals. Ann Surg 1979: 190: .. 61-.473. 
27. Hamburger J. Yaysse J. Crosnier J. et al. Renal homo-
transplantatIOn in man after radiatIOn of the recipient. 
Am J Med 1962:32:85 .. -871. 
28. Kuss R. Legraln M. Mathe G. ct al. Homologous 
human kidney transplantation. E:l.penence with six 
patients. Postgrad Mt:d J 19SO:gU:ROU~RP J. 
29. ;vlurrav.lE. ~lerrill lP. Dammln GJ. t:t al. Kidney trans-
plantation in modified reClptents. Ann Surg 1962: 156: 
337-355. 
30. Iv.lceker W. Condie R. Weil1l'r D. et al. Prolongation of 
skin homograft survival in rahhits hy 6-mcrcaptopurine. 
Proc Soc Exp Bioi Mel! 1959: I 02:"S9-.46 I. 
31. Schwartz R. Dameshek W The effects of 6-mercapto-
purine on hllll1ogr;ltt reactions. J Clin Invest 1960:39: 
9pO~9:;u 
~OK Caine RY. The reJcction of rt:nal ljEll1jEl~rafts: inhibition 
in dogs hy 6-lI1ercaptopurine. Lancet 1960: I : .. 17-.4 I 8. 
.13. Zukoskl CF. Let: HM. Humt: DM. The prolongation of 
functional surVival of call1ne renal homografts by 6-
mcrcaptnpurint:. Surg Forum 1')60: 11: .. 70-.472 . 
. '-1. Caine RY. Inhihilinn of the rejt:ction of renal homo-
grafts tn dogs wtth pUflnt: analogues. Transplant Bull 
1961 :28: .... 'i 
Y'. Elion (iB. Bit:ht:r S. f1itcllln~s (iH. The fate of 6-mer-
captopurine 111 mice. Ann :-I Y Acad Sci 1')5):60: 
297-303. 
.16. Schwam R. Damt:shek W Drug-induced immunologi-
cal toleram:e. :'oJatun: 19'i9:18.1: 1S!iO~fEFhP . 
. n. Murrav lE. tvh:rrill 11'. I1arrisnn JlI. et al. Prolonged 
survival of human-l-..idnl'Y hll1logr~lfts hy Immunosup-
pressive drug tht:rapy. N Engl J Med 1963:268: 
1K11R~1K1OPK 
38. Starzl TE. \1archwfl) TL. Waddt:il WR. Tht: reversal of 
rejeCll()n In human renal Illlmogratts WIlh suhse4uent 
dcvelopll1t:nt of homograft toier;tnce. Surg (ivnecol 
Ohstet 1%.': I 1T:KyUR~KylgpK 
.19. Starzl TE. :-'larl'illl'fl) 1'1 .. Porter K:\. ct al. The use of 
heterologous antrlvmphOld a,:ents III ,'anlllC renal and 
Ilyer h011lotransplant:!t,,'n and III human renal homo-
transplantallon. pur~ li~ newl Onslet 1<)67: 12 .. :.10 I ~_I 18. 
.. t). Caine RY. Rolles K. White D1G. et al. C~cfEFsporin A 
lllillall\ as the only illllllltnOsUppressantln .14 reCIpients 
"f ,:aJavcnc llfgans: .12 I-..Idncys . .2 pancrease,. and :2 
livers. Lancci 1<)79:2: I MPK1~ 1 036. 
12 ANESTHESIA AND TRANSPLANTATION 
41. Starzl TE. Todo S. Fung 1. ct al. FK 506 for human 
liver. kidney. and pancreas transplantation. Lancet 
1989;2: 1000-1004. 
42. Bach F. Hirschhorn K. Lymphocyte interaction: a 
potential histocompaubility test in vitro. Science 
1964: 143:813-814. 
43. Bain B. Vas MR. Lowenstein L. The development of 
large immature mononuclear cells in mixed leukocyte 
cultures. Blood 1964:23:108-116. 
44. Snell GD. The homograft reaction. Annu Rev Micro-
bioi 1957; II :439-458 .. 
45. Steinmuller D. Immunization with skin isografts taken 
from tolerant mice. Science 1967;158:127-129. 
46. Starzl TE. Demctris A1. Murase N. et al. Cell migra-
tion. chimerISm. and graft acceptance. Lancet 1992; 
339: 1579-1582. 
47. Starzl TE. Demetris AJ. Trucco M. et al. Cell migration 
and chimerism after whole organ lrJJ1spJantation: the basis 
of graft acceptanct!. Hepatology 1993: 17: 1127-1152. 
48. Demetns A1. Murase N. Fujisaki S. et al. Hematolym-
phoid cell trafticking. microchimerism. and GVHD 
reactions after liver. bone marrow. and heart transplan-
tation. Transplant Proc 1993:25:3337-3344. 
49. Qian S. Demetns AJ. Murase N. et al. Murine liver allo-
graft transplantatIOn: tolerance and donor cell chimerism. 
Hepatology 1994: 19:916-924. 
50. Steinman RM. Cohn ZA. Identitication of a novel cell 
type in peripheral lymphoid organs of mice. I. Mor-
phology. quanutatlOn. tissue distribution. 1 Exp Med 
1973:137: 1142-1162. 
51. Steinman RM. The dendritic cell system and its role in 
immunogemcity. Annu Rev Immunol 1991 ;9:271-296. 
52. ~fonaco AP. Clark AW. Brown RW. Active enhance-
ment of a human cadaver renal allograft with ALS and 
donor bone marrow: case report of an initial attempt. 
Surgery 1976;79:384-392. 
53. Barber WHo Mankin 1A. Laskow DA. et al. Long-term 
results of a controlled prospective study with transfusion 
of donor specific bone marrow in 57 cadaveric renal allo-
graft reCIpients. Transplantation 1991 :51 :70-75. 
54. Salvatierra 0 Jr. Vincenti F. Amend WJ. et al. Deliber-
ate donor-~pecitlc blood transfusions prior to living 
related renal transplantation. A new approach. Ann Surg 
1980: 192:543-552. 
55. Anderson CB. Sicard GA. Etheredge EE. Pretreatment 
of renal allograft recipients with azathioprine and 
donor-specific blood products. Surgery 1982;92: 
315-341. 
56. Sollinger HW. Burlingham WJ, Sparks EM. et al. 
Donor-specific transfusions in unrelated and related 
HLA-mismatched donor-recipient combinations. Trans-
plantation 1984:38:612-615. 
57. Fontes P. Rao A, Demetris AJ. et al. Augmentation with 
bone marrow of donor leukocyte migration for kidney. 
liver. heart. and pancreas islet transplantation. Lancet 
1994:344: 151-155. 
58. Przepiorka D. Thomas ED. Durham DM. Fisher L. Use 
of a probe to repeat sequence of the Y chromosome for 
detection of host cells in peripheral blood of bone mar-
row transplant recipients. Hematopathology 1991 ;95: 
201-206. 
59. Wessman M. Popp S. Ruutu T. et al. Detection of resid-
ual host cells after bone marrow transplantation using 
non-isotopic in situ hybridization and karyotype analy-
sis. Bone Marrow Transplant 1993; II :279-284. 
60. Starzl TE. Zinkernagel RM. Antigen localization and 
migration in immunity and tolerance. N Engl J Med (in 
press). 
61. Starzl TE. Demetris AJ, Trucco M. et al. Chimerism 
after liver transplantation for type IV glycogen storage 
disease and type I Gaucher's disease. N Engl 1 Med 
1993:328:745-749. 
62. Starzl TE. Fung 1. Tzakis A. et al. Baboon to human 
liver transplantation. Lancet 1993;341 :65-71. 
63. Cohn M. The wisdom of hindsight. Annu Rev 
Immunology 1994: 12: 1-62. 
64. Mitchison NA. Better to Confess Ignorance. [n Answer 
to Melvin Cohn. In MM Burger. B Sordat. RM Zinker-
nagel (eds). Cell to Cell Interaction. Switzerland: Basel 
Karger 1990:232-234. 
65. Simonsen M. On the acqUisition of tolerance by adult 
cells. Ann NY Acad Sci 1960:87:382-390. 
6ti. Simonsen M. Graft versus host reactions. Their natural 
history. and applicability as tools of research. Prog 
Allergy 1962:6:349-467. 
67. Michie D. Woodruff MFA. Zeiss 1M. An investigation 
of immunological tolerance based on chimera analysis. 
Immunology 1961 :4:413-424. 
